ASCO 2024 | EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC

Antonio Giordano, MD, PhD, Dana Farber Cancer Institute, Boston, MA, discusses results from the Phase II EV-202 study (NCT04225117) of enfortumab vedotin (EV) monotherapy in patients with triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer. Eligible patients had prior treatments, including taxanes or anthracyclines. Antitumor activity was observed in both cohorts, and safety was manageable, with common grade ≥3 treatment-related adverse events including neutropenia and skin reactions. These findings support potential of EV in patients with heavily pretreated breast cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.